Recurrence and mortality after achieving PR: univariate analysis of anti-FVIII IgA and other baseline characteristics
| Baseline variable . | Recurrence, n (%) . | Death, n (%) . | Recurrence-free survival (days), median (95% CI) . | HR (95% CI) . | P value . |
|---|---|---|---|---|---|
| Anti-FVIII IgA | |||||
| Positive (n = 29) | 13 (45) | 11 (38) | 81 (53-109) | 2.17 (1.13-4.20) | .021 |
| Negative (n = 41) | 12 (29) | 6 (15) | Not reached | ||
| Factor VIII activity | |||||
| <1 IU/dL (n = 31) | 10 (26) | 9 (23) | 113 (0-316) | 1.75 (0.92-3.35) | .089 |
| ≥1 IU/dL (n = 39) | 15 (48) | 8 (26) | Not reached | ||
| FVIII inhibitor | |||||
| ≤20 BU/mL (n = 39) | 15 (38) | 9 (23) | 119 (83-155) | 1.30 (0.67-2.52) | .431 |
| >20 BU/mL (n = 31) | 10 (32) | 8 (26) | Not reached | ||
| Gender | |||||
| Female (n = 33) | 9 (27) | 5 (15) | Not reached | 0.54 (0.28-1.04) | .067 |
| Male (n = 37) | 16 (43) | 12 (32) | 112 (85-139) | ||
| Age | |||||
| ≤74 y (n = 40) | 15 (38) | 10 (25) | 404 (0-923) | 0.86 (0.45-1.66) | .652 |
| >74 y (n = 30) | 10 (33) | 7 (23) | 135 (0-315) | ||
| WHO-PS | |||||
| Good (≤ 2, n = 45) | 18 (40) | 5 (11) | Not reached | 0.55 (0.28-1.05) | .071 |
| Poor (> 2, n = 25) | 7 (28) | 12 (48) | 93 (0-203) | ||
| Underlying disorder | |||||
| Autoimmunity (n = 13) | 6 (46) | 3 (23) | 78 (0-220) | 1.77 (0.84-3.76) | .136 |
| Malignancy (n = 6) | 3 (50) | 3 (50) | 109 (0-235) | 2.19 (0.84-5.68) | .109 |
| Pregnancy (n = 5) | 2 (40) | 0 (0) | Not reached | 0.75 (0.18-3.12) | .691 |
| Baseline variable . | Recurrence, n (%) . | Death, n (%) . | Recurrence-free survival (days), median (95% CI) . | HR (95% CI) . | P value . |
|---|---|---|---|---|---|
| Anti-FVIII IgA | |||||
| Positive (n = 29) | 13 (45) | 11 (38) | 81 (53-109) | 2.17 (1.13-4.20) | .021 |
| Negative (n = 41) | 12 (29) | 6 (15) | Not reached | ||
| Factor VIII activity | |||||
| <1 IU/dL (n = 31) | 10 (26) | 9 (23) | 113 (0-316) | 1.75 (0.92-3.35) | .089 |
| ≥1 IU/dL (n = 39) | 15 (48) | 8 (26) | Not reached | ||
| FVIII inhibitor | |||||
| ≤20 BU/mL (n = 39) | 15 (38) | 9 (23) | 119 (83-155) | 1.30 (0.67-2.52) | .431 |
| >20 BU/mL (n = 31) | 10 (32) | 8 (26) | Not reached | ||
| Gender | |||||
| Female (n = 33) | 9 (27) | 5 (15) | Not reached | 0.54 (0.28-1.04) | .067 |
| Male (n = 37) | 16 (43) | 12 (32) | 112 (85-139) | ||
| Age | |||||
| ≤74 y (n = 40) | 15 (38) | 10 (25) | 404 (0-923) | 0.86 (0.45-1.66) | .652 |
| >74 y (n = 30) | 10 (33) | 7 (23) | 135 (0-315) | ||
| WHO-PS | |||||
| Good (≤ 2, n = 45) | 18 (40) | 5 (11) | Not reached | 0.55 (0.28-1.05) | .071 |
| Poor (> 2, n = 25) | 7 (28) | 12 (48) | 93 (0-203) | ||
| Underlying disorder | |||||
| Autoimmunity (n = 13) | 6 (46) | 3 (23) | 78 (0-220) | 1.77 (0.84-3.76) | .136 |
| Malignancy (n = 6) | 3 (50) | 3 (50) | 109 (0-235) | 2.19 (0.84-5.68) | .109 |
| Pregnancy (n = 5) | 2 (40) | 0 (0) | Not reached | 0.75 (0.18-3.12) | .691 |
Hazard ratios and P values are from univariate log-rank tests for recurrence-free survival. See “Results” for information on multivariate analysis.
HR, hazard ratio.